RT Journal Article SR Electronic T1 Pembrolizumab Yields Lasting Merkel Cell Carcinoma Responses JF Cancer Discovery JO Cancer Discov FD American Association for Cancer Research SP 566 OP 566 DO 10.1158/2159-8290.CD-NB2016-050 VO 6 IS 6 YR 2016 UL http://cancerdiscovery.aacrjournals.org/content/6/6/566.1.abstract AB In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.